Findings

What do systematic reviews say?

7 questions · 7 findings · 4 reviews

No studies found 0 · 0%GRADE not reported 2 · 28.6%Very low 0 · 0%Low 2 · 28.6%Moderate 3 · 42.9%High 0 · 0%

Serious adverse events · people with CIDP

Intravenous immunoglobulin showed no clear difference in serious adverse events compared with intravenous methylprednisolone (moderate certainty).

1 finding from 1 review

Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy 2024 · Cochrane Headline outcomes only
RR 4.4 [0.22, 86.78]
1 study · 45 participants
Moderate

Serious adverse events · people with CIDP

Intravenous immunoglobulin showed no clear difference in serious adverse events compared with prednisolone (moderate certainty).

1 finding from 1 review

Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy 2024 · Cochrane Headline outcomes only
RR 0.45 [0.04, 4.69]
1 study · 57 participants
Moderate

Serious adverse events · people with CIDP

Intravenous immunoglobulin showed no clear difference in serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy 2024 · Cochrane Headline outcomes only
RR 0.82 [0.36, 1.87]
3 studies · 315 participants
Moderate

Serious adverse events · people with CIDP

1 finding from 1 review

Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 20 participants
GRADE not reported

Adverse events · adults with renal vasculitis

Intravenous immunoglobulin may leads to higher adverse events compared with placebo (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 3
1 study · 34 participants
Low

Significant adverse events · people with inclusion body myositis

1 finding from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 78 participants
GRADE not reported

SAEs · NSTI

Intravenous immunoglobulin showed no clear difference in serious adverse events (SAE) compared with placebo (low certainty).

1 finding from 1 review

Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
RR 0.73 [0.32, 1.65]
1 study · 100 participants
Low